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Abstract
Background: TheWorld Health Organization recommendsmolecular tests Polymerase
Chain Reaction (PCR) to the diagnosis of coronavirus disease of 2019 (COVID-19),
which detect the Severe Acute Respiratory Syndrome (SARS-Coronavirus 2) virus RNA.
However, these tests are expensive and give a high negative result. There were urgent
medical and public health needs for early diagnosis and treatment to minimize the
spread of COVID-19. This review aimed to summarize known to date information about
the latest research progress of the sensitivity and specificity of rapid combined IgM/IgG
antibody test to diagnose the pandemic novel coronavirus disease of 2019 (COVID-19).
Methods:Databases such as PubMed, Google Scholar, Science Direct, Web of Science
electronic databases were search related articles published between January 23,
2020 and April 29, 2020, using the following search terms: “COVID19 or COVID-19,”
“novel coronavirus,” “SARS CoV-2 or SARS CoV2,” “Rapid antibody test,” “IgM/IgG,”
“sensitivity,” “specificity.”
Results: The review included eight clinical studies for a total of 782 patients
with COVID-19 and 631 healthy controls. The sensitivity and specificity of gold
chromatography immuno-assays (GCIAs) IgM/IgG rapid test vary greatly among
published studies. Of the eight shortlisted studies, the IgM/IgG sensitivity ranged
from 73.9% to 89.3% in six (75%) and the IgM/IgG specificity ranged from 88.9%
to 100% in the eight (100%) reviewed studies. The pooled data revealed that the
average sensitivity and specificity was 70% and 94.5%, respectively. They agreed on
its simplicity, fastness, and fewer requirements.
Conclusion: The GCIAs IgM/IgG rapid tests are simply fast and safe. Besides their short
turnaround time, no specific equipment or skilled technicians’ requirements, they can
serve as a rapid diagnostic test of RT–PCR-negative highly suspected patients and
screening of SARS CoV-2 carriers. It cannot take the place of PCR, but the huge lab
diagnosis pressure can be greatly relieved and more research is needed to detect its
reliability and clinical utility in limited-resource settings.
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1. Introduction
Coronavirusesare a large group of viruses that belong to Coronaviridae family. These
viruses are enveloped RNA viruses, surrounded by a club-like projection (spikes) on the
outer surface, which give the virus a crown-shaped appearance [1]. They were known
to cause acute respiratory diseases such as Middle East Respiratory Syndrome (MERS)
and Severe Acute Respiratory Syndrome (SARS) [2].
The World Health Organization officially named the novel coronavirus 2019-nCoV as
SARS CoV-2 and the disease as coronavirus disease 19 (COVID-19) [3]. On December 12,
2019, patients with pneumonia of unknown origin were identified, which was followed
by an outbreak in Wuhan city, China on December 31, 2019. The Chinese Center for
Disease Control and Prevention (China CDC) detected the novel coronavirus in samples
of the lower respiratory tract from patients with pneumonia and discovered the genomic
sequence on January 11, 2020. OnMarch 11, 2020, theWHOdeclared COVID19 outbreak
a global pandemic [4]. As of April 29, 2020, WHO had reported 2,954,222 confirmed
cases and 202,597 death worldwide [5]. Bats have been suspected as the natural host
origin of the virus by several studies, and is transmitted to humans through unknown
intermediate host[6]. The disease is highly infectious, and human-to-human transmission
occurs due to close contact with a person with respiratory symptoms such as sneezing
and coughing. The aerosols and droplets reach the lungs through inhalation via the
mouth and nose [2] . Also, fecal-oral transmission and transmission via vomits have
been reported [7, 8].
The clinical features of COVID-19 are highly nonspecific and varied, ranging from
asymptomatic to severe pneumonia, respiratory failure, and even death in certain cases
[4, 9]. The main symptoms reported were sore throat, dry cough, fever, chills, headache,
fatigue, muscle and joint pain, sputum production, shortness of breath, conjunctival and
nasal congestion [4, 10]. The digestive symptoms such as diarrhea, nausea, or vomiting
cab be an early sign of infection [11]. Approximately 80% of the people infected with
SARS CoV-2 had mild to moderate disease and recovered, which includes pneumonia
and non-pneumonia cases. The evere disease was reported to have occurred in about
13.8% and the symptoms included dyspnea or high respiratory rate (≥ 30 breath/min),
low pulse oxygen saturation (≤ 93%), and low PaO2/FiO2 ratio (< 300). About 6.1%
represent the critical cases that include respiratory failure, septic shock, and multiple
organ dysfunction [12]. The high-risk factors for severe disease and death include cancer,
people aged> 60 years, and chronic diseases such as cardiovascular disease, diabetes,
hypertension, and chronic respiratory disease [4, 15]. The disease in children aged <
19 years was rare and mild, and a very small proportion of them developed severe or
critical condition [4, 12, 14].
The diagnosis of COVID-19 is based on clinical symptoms, epidemiological history,
and auxiliary examination such as Real Time-PCR (RT-PCR) for virus nucleic acid, CT
DOI 10.18502/sjms.v15i5.6969 Page 72
Sudan Journal of Medical Sciences Ehab Mohammed Elmadenah Mohammed et al
imaging, liver enzymes, serological tests, blood culture, and some hematological param-
eters [16]. However, since the clinical manifestations were highly atypical, auxiliary
examinations were necessary as primary tools for the diagnosis [17].
Currently, RT-PCR for virus nucleic acid (RNA) is considered as the gold standard for
detecting SARS Cov-2 [18]. The RNA virus is detected using lower and upper respiratory
samples. The upper respiratory samples such as nasopharyngeal swabs, oropharyn-
geal swabs, nasopharyngeal washes, and nasal aspirates were recommended in the
reviewed studies. However, the lower respiratory samples such as sputum, endotracheal
aspirates, and Broncho Alveolar Lavagewere recommended for patients with productive
cough (19). In severe cases, the virus nucleic acid (RNA) may also be detected in the stool
(9). Although RT-PCR is considered as a standard method for the diagnosis because
they identify the specific sequence of the pathogen, it also has a high false-negative
rate [19, 20].
As an alternative to RT-PCR, computed tomography (CT scan) can also be used for
the clinical diagnosis of COVID-19, as a CT scan is more sensitive and specific, and
can therefore be used to diagnose asymptomatic and suspect patients with negative
molecular diagnosis [9]. Overall, CT imaging revealed infiltrates, ground glass appear-
ance, and consolidation with or without vascular enlargement [21], as well as interlobular
septal thickening, in comparison to images of healthy lungs [22].
Generally, the laboratory examination results are highly non-specific. The white blood
cell counts (WBCs) and the platelet count were usually normal or decreased with lym-
phopenia [6]. The level of C-reactive protein (CRP) and erythrocyte sedimentation rate
(ESR) were generally elevated [23]. However, in severe cases, neutrophils counts were
high whereas lymphocyte counts were low [6]. The level of alanine aminotransferase
(ALT), aspartate aminotransferase (AST), procalcitonin, prothrombin time, creatinine, D-
dimer, creatine phosphokinase (CPK), and lactate dehydrogenase (LDH) were increased
[24, 25].
Several serological tests for the measurement of specific IgM/IgG antibody in sera
of COVID-19 patients developed and were pre-tested by some companies, such
as Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay
(MAGLUMI 2000 Plus CLIA), and Point of Care Testing (POCT), but very few articles were
published. While immunoglobulin IgG indicates recent and past infection, IgM indicates
current infection [26]. The serological test may help in the diagnosis of a patient
suspected with COVID-19 with a negative RT-PCR result and in the documentation of
asymptomatic infection [23]. The sensitivity of the assay is the ability to correctly detect
positive cases, whereas specificity is the ability to correctly detect negative cases. So,
highly sensitive test means there were few false-negative results and a highly specific
test mean there were few false-positive results [27]. There are urgent medical and public
health needs of a sensitive and specific test for the early diagnosis and treatment to
minimize the spread of COVID-19.
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2. Materials and Methods
A search was run for articles on COVID-19 by using electronic databases such as
PubMed, Google Scholar, Science Direct, supplemented by Web of Science electronic
databases, using the following search terms: “COVID19 or COVID-19,” or “novel coro-
navirus,” “SARS CoV-2,” “SARS CoV2,” “rapid antibody test,” “IgM/IgG,” “sensitivity,”
and “specificity.” The full-text articles were identified and screened for original data.
The reference lists were retrieved and checked manually for further relevant studies.
Studies were included when the article was published in the English language and
referred to humans.
3. Results
The studies were retrieved between January 23, 2020 and April 29, 2020. A total of 142
titles were retrieved, and after removing duplication and excluding articles that did not
meet the inclusion criteria, eight studies were included in the review and considered as
eligible.
In the eight included studies, a total of 782 cases were reported, of which, 707 were
confirmed cases for COVID-19 by PCR, 75 were negative PCR but with signs of COVID-
19, and 631 were healthy controls (see Table 1). The study populations of the three studies
were grouped according to the time of disease onset. Six studies detected SARS CoV-2
IgM/IgG antibody in serum, whereas two studies detected it in whole blood. All studies
considered PCR as the gold standard. Only one study imported from Denmark aimed
to evaluate the sensitivity and specificity of six commercially available points of care
IgM/IgG rapid tests and the rest of the studies were imported from China aimed to
evaluate commercially available point of care IgM/IgG rapid test, see Table 2.
TABLE 1: Sensitivity and specificity of combined IgM/IgG rapid tests
No. Author Study population Sensitivity% Specificity%
PCR+ve PCR–ve Healthy IgM/IgG IgM/IgG
1 (Li et al., 2020) [27] 397 128 88.7 90.3
2 (Hoffman et al., 2020) [28] 29 124 81.1 99.6
3 (Cassaniti et al., 2020) [29] 38 12 30 18.4 91.7
4 (Dohla et al., 2020) [30] 39 10 36.4 88.9
5 (Ying et al., 2020) [31] 90 89 85.6 91
6 (Xiang et al., 2020) [32] 29 124 82.4 100
7 (Perez et al., 2020) [33] 55 63 45 73.9 100
8 (Lassauniere et al., 2020) [34] 30 81 89.3 94.5
4. Discussion
Although, currently, RT PCR is considered as a gold standard test for COVID-19, this
technique is expensive, requires high-quality and well-equipped laboratory facilities,
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TABLE 2: Manufacturer information of IgM/IgG rapid test
No. Reference No. Product Name
1 [27] SARS Cov-2 Rapid IgG/IgM combined antibody Test Kit/Jiangsu
Medomics Medical Technologies, Nanjing, China.
2 [28] COVID19 IgG/IgM Rapid Test Cassette/Zhejiang orient Gene Biotech Co.
Ltd, Huzhou, Zhejiang, China.
3 [29] VivaDiag COVID19 IgM/IgG Rapid Test/Vivacheck Biotech Co. Ltd, China.
4 [30] Not mentioned
5 [31] SARS cov-2 IgG/IgM Antibody Test Kit/Chinese Biotechnology Company,
China.
6 [32] Novel Coronavirus IgG/IgM Antibody GICA Kit/Zhu Hai Liv Zon Diagnostic
Inc., China.
7 [33] COVID19 IgG/IgM/All Test Biotech, Hangzhou, China.
8 [34] 2019 n COV IgG/IgM Rapid test/Dynamiker Biotechnology, Tianjin, China.
Anti-SARScov-2 Rapid Test/Auto Bio Diagnostics, Zhengzhou, China.
2019 n COV IgG/IgM Rapid test cassette/Hangzhou All test Biotech,
Hangzhou, China.
On-Site TM COVID19 IgG/IgM Rapid Test/CTK Biotech, Poway, CA, USA.
2019 n COV IgG/IgM Rapid Test Cassette/Acro Biotech, Rancho
Cucamonga, CA, USA.
Coronavirus Diseases 2019 (COVID19) IgG/IgM Antibody Test/Artorn
Laboratories, Burnaby, Canada.
trained staff, and has a high false-negative results rate [19, 20, 25]. The possible
explanation for the high false-negative results is that SARS CoV2 infection mainly occurs
in the lungs (lower respiratory tract), whereas the samples are taken mostly from the
upper respiratory tract. Wang et al. reported that the RT-PCR of nasal and pharyngeal
swab detected virus only in two-third and one-third of cases, respectively, and the rates
of the positive result were 63% and 32%, respectively, when compared to Broncho-
alveolar lavage fluid and sputum, 93% and 72%, respectively [36]. However, according
to Ren et al., the sensitivity and specificity of RT-PCR for pharyngeal swab were 98.8%
and 78.2%, respectively [37].
The GCIA, on the other hand, is a rapid serological test for the detection of IgM/IgG
combined antibody of SARS CoV2, and can give the result in less than 15 min without
the requirement of high-quality and well-equipped laboratory facilities, trained staff,
or specimen transportation as compared to PCR [32]. It remains a good choice in
developing countries such as Sudan. IgM antibody can be detected in the blood
specimen after three–six days, while IgG is detected after eight days of disease onset
(38). The current review showed that eight studies used the GCIA for the IgM/IgG
antibody. The GCIA is simple and provides a rapid diagnosis for COVID19. However,
when the specimen is collected in the early stage of the disease onset, the false-
negative result rate was high [15].
Further, Li et al. reported the sensitivity and specificity of IgM/IgG as 88.7% and
90.6%, respectively. They explained that the false-negative was due to low antibody
concentration, the differences in immune response between individuals, decrease and
disappeared IgM antibody after two weeks, and difficulties in knowing the exact time of
infection [28]. Likewise, Xiang et al. reported a sensitivity and specificity of IgM/IgG as
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82.4%, and 100%, respectively [33]. Hoffman et al., in their study, found the sensitivity of
IgM and IgG to be 69% and 93.1% and the specificity to be 100% and 99.2%, respectively.
They observed one false-positive result for IgG from healthy control group sample
collected in 2018; this result indicates cross-reaction between SARS-CoV and SARS-
CoV2 or another human coronavirus [29].
Further, Hoffman et al. grouped the patients into two categories according to the time
of disease onset and found no significant difference in the IgM and IgG between the
two groups. They concluded that the performance of IgM/IgG rapid test was satisfactory
[29]. Also, Perez et al. and Ying et al. found that the sensitivity and of IgM/IgG were
73.9% and 82.4% and the specificity were 100% and 100%, respectively. Perez et al. and
Ying et al. categorized the cases into three groups according to the time of disease
onset and found an increase in the positivity rate for IgM/IgG from 7–13 days to ≥ 14
days [32, 34].
Although Lassauniere et al. used the same kit as Perez et al., the sensitivity and
specificity was, however, 100% and 87%, respectively. These differences may probably
be due to the differences in the setting or the study population [34, 35]. Perez et al.
concluded that the immune-chromatography test is considered as a reliable diagnostic
test for SARS CoV2 infection from 14 days of disease onset [34], and Ying et al.
concluded that the sensitivity and specificity of the GCIA for IgG/IgM combined test
were good [32].
On the other hand, Cassaniti et al. and Dohla et al. found that the sensitivity and
specificity of IgM/IgG were 18.4% and 36.4%, and 91.7% and 88.9%, respectively, and
additionally due to poor sensitivity, they concluded that COVID19 IgM/IgG rapid diag-
nostic test is not recommended for a patient with suspected COVID-19 [30, 31]. Perhaps,
the low sensitivity may be due to samples taken in the early onset of the disease. Dohla
et al. recommend the acceleration of improvement and assessment of the effective
point of the care test system [31]. Currently, the available serological tests use antibodies
against either nucleocapsid protein (N) or spike protein (S) on the surface of SARS COV-
2 [39]. Previous studies reported that the sensitivity and specificity of assays that used
antibodies against S protein were high because the S protein is highly immunogenic and
its affinity to angiotensin-converting enzyme receptor2 (ACE2) correlated with infectivity
[40, 41]. Hence, IgM/IgG tests may be of help for the diagnosis when there is a positive
test result accompanied with repeated negative RT-PCR in a highly suspected patient
and for rapid screening of SARS CoV-2 carriers in limited-resource countries like Sudan
where people are used to present late. Also, it can be used to screen health workers
following isolation and for management using convalescence plasma. Additionally, the
huge laboratory diagnosis pressure can be greatly relieved; also giving value to the
diagnosis and treatment.
5. Limitations
The main limitation of the current study was that seven studies were from the same
country (China) and only one from Denmark. Not all studies grouped the population
according to disease onset. There were differences in sample size and the type of SARS
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CoV-2 antigen targeted in assay between the studies. The cross-reactivity between
SARS-CoV and another human coronavirus might have happened.
6. Conclusion
The sensitivity and specificity of the GCIA for IgM/IgG vary greatly among published
studies. Of the eight reviewed studies, the IgM/IgG sensitivity ranged from 73.9% to
89.3% in six (75%) and from 88.9% to 100% in all the reviewed studies (100%). They
agreed that IgM/IgG rapid test are good, as besides being rapid, they do not need any
special equipment or skilled staff. Although it cannot replace PCR, it can serve as a
rapid diagnostic test for RT-PCR-negative highly suspected patients and screening of
SARS CoV-2 carriers in limited-resource countries, and the massive laboratory diagnosis
pressure can be highly relieved. Furthermore, it can be used for management using
convalescent plasma and screening of health workers following isolation. More research
is needed to detect its reliability and clinical utility in limited-resource settings.
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